Stay updated on Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.

Latest updates to the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page updated the revision label from v3.6.5 to v3.6.6, indicating a newer version of the study documents; this appears to be an administrative update rather than a substantive change to study information.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5. This signals a new site revision without changes to study content.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3. This indicates a small release update applied to the page’s underlying platform.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page revision line was updated from v3.6.2 to v3.6.3, indicating a small metadata update to the page without changes to the study information.SummaryDifference0.1%

- Check76 days agoChange DetectedThe study record revision was updated from v3.6.0 to v3.6.2, indicating a newer version of the documentation. This update appears administrative rather than affecting the study details.SummaryDifference0.1%

- Check90 days agoChange DetectedEnrollment status updated to no longer recruit participants, and new sections including How to Read a Study Record, Common Questions, How to Join a Study, and the Intervention/Treatment area were added, along with a revision notice (Revision: v3.6.0).SummaryDifference0.4%

Stay in the know with updates to Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat Plus Pembrolizumab in Gastric Cancer Clinical Trial page.